- Home
- NVCR vs VERA Comparison
NVCR vs VERA Comparison
Compare NVCR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- VERA
- Stock Information
- Founded
- NVCR 2000
- VERA 2016
- Country
- NVCR Switzerland
- VERA United States
- Employees
- NVCR N/A
- VERA N/A
- Industry
- NVCR Medical/Dental Instruments
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- VERA Health Care
- Exchange
- NVCR Nasdaq
- VERA Nasdaq
- Market Cap
- NVCR 1.9B
- VERA 2.0B
- IPO Year
- NVCR 2015
- VERA 2021
- Fundamental
- Price
- NVCR $17.71
- VERA $24.00
- Analyst Decision
- NVCR Buy
- VERA Buy
- Analyst Count
- NVCR 6
- VERA 8
- Target Price
- NVCR $32.83
- VERA $64.63
- AVG Volume (30 Days)
- NVCR 1.6M
- VERA 2.3M
- Earning Date
- NVCR 07-24-2025
- VERA 08-07-2025
- Dividend Yield
- NVCR N/A
- VERA N/A
- EPS Growth
- NVCR N/A
- VERA N/A
- EPS
- NVCR N/A
- VERA N/A
- Revenue
- NVCR $621,711,000.00
- VERA N/A
- Revenue This Year
- NVCR $5.56
- VERA N/A
- Revenue Next Year
- NVCR $9.19
- VERA N/A
- P/E Ratio
- NVCR N/A
- VERA N/A
- Revenue Growth
- NVCR 18.27
- VERA N/A
- 52 Week Low
- NVCR $14.17
- VERA $18.53
- 52 Week High
- NVCR $34.13
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- NVCR 51.32
- VERA 54.33
- Support Level
- NVCR $17.53
- VERA $22.76
- Resistance Level
- NVCR $18.70
- VERA $23.97
- Average True Range (ATR)
- NVCR 0.72
- VERA 1.21
- MACD
- NVCR 0.09
- VERA 0.15
- Stochastic Oscillator
- NVCR 60.56
- VERA 73.63
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.